Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

PURPOSE: Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial a...

Descripción completa

Detalles Bibliográficos
Autores principales: Catenacci, Daniel V.T., Junttila, Melissa R., Karrison, Theodore, Bahary, Nathan, Horiba, Margit N., Nattam, Sreenivasa R., Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M., de Sauvage, Frederic J., Kindler, Hedy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2015
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678179/
https://www.ncbi.nlm.nih.gov/pubmed/26527777
http://dx.doi.org/10.1200/JCO.2015.62.8719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678179/
https://www.ncbi.nlm.nih.gov/pubmed/26527777
http://dx.doi.org/10.1200/JCO.2015.62.8719

Ejemplares similares